Head to Head Analysis: Tilray (TLRY) & The Competition

Share on StockTwits

Tilray (NASDAQ: TLRY) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Tilray to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tilray and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray 1 12 2 0 2.07
Tilray Competitors 135 359 403 14 2.32

Tilray currently has a consensus price target of $12.73, indicating a potential upside of 158.68%. As a group, “Medicinals & botanicals” companies have a potential upside of 111.15%. Given Tilray’s higher probable upside, analysts plainly believe Tilray is more favorable than its rivals.

Risk and Volatility

Tilray has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Comparatively, Tilray’s rivals have a beta of 2.57, indicating that their average share price is 157% more volatile than the S&P 500.

Institutional & Insider Ownership

10.4% of Tilray shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Tilray and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tilray $166.98 million -$321.17 million -2.91
Tilray Competitors $219.25 million -$99.48 million 2.24

Tilray’s rivals have higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Tilray and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tilray -259.60% -77.77% -21.45%
Tilray Competitors -1,150.45% -258.05% -48.97%

Summary

Tilray rivals beat Tilray on 8 of the 13 factors compared.

Tilray Company Profile

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

125 Shares in UnitedHealth Group Inc  Acquired by Old North State Trust LLC
125 Shares in UnitedHealth Group Inc Acquired by Old North State Trust LLC
Johnson & Johnson  Shares Sold by Old North State Trust LLC
Johnson & Johnson Shares Sold by Old North State Trust LLC
Old North State Trust LLC Has $1.47 Million Position in The Procter & Gamble Company
Old North State Trust LLC Has $1.47 Million Position in The Procter & Gamble Company
Johnson & Johnson  Position Cut by Lincoln Capital LLC
Johnson & Johnson Position Cut by Lincoln Capital LLC
Microsoft Co.  Stake Decreased by Lincoln Capital LLC
Microsoft Co. Stake Decreased by Lincoln Capital LLC
Old North State Trust LLC Sells 1,862 Shares of Intel Co.
Old North State Trust LLC Sells 1,862 Shares of Intel Co.


 
© 2006-2020 Zolmax.